US Patent Issued to IntraBio on June 30 for "Treatment of late-onset neurodegenerative diseases in heterozygous NPC1 gene mutation carriers" (German Inventor)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,667,550, issued on June 30, was assigned to IntraBio Ltd. (London).

"Treatment of late-onset neurodegenerative diseases in heterozygous NPC1 gene mutation carriers" was invented by Michael Strupp (Munich).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of treating, preventing, or delaying the onset of a late-onset neurodegenerative disease, e.g., Niemann-Pick type C, or a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of acetyl-leucine to the subject, wherein the subject is heterozygous NPC1 gene mutation carrier."

The patent was filed on Jan. 13, 2021, und...